Mr. Thomas Smeenk reports

HEMOSTEMIX PROVIDES CORPORATE UPDATE

At the request of the Canadian Investment Regulatory Organization (CIRO), Hemostemix Inc. is issuing this news release to clarify and provide additional information regarding its previous announcement dated Feb. 10, 2025.

On Feb. 10, 2025, Hemostemix announced the engagement of Proconsul Capital Ltd. to provide investor relations services. The company wishes to provide the following additional details in accordance with TSX Venture Exchange Policy 3.4, Section 3.1.

1. Details of the investor relations agreement:
   1. Service provider: Proconsul Capital Ltd.;
   2. Services provided: investor relations and market awareness services;
   3. Duration of engagement: Feb. 6, 2025;
   4. Compensation: $6,000 per month for the term of the engagement, which is month to month.
2. Details of any stock option grant: No stock options have been granted. At the end of the third month of engagement, the company and ProCounsel may negotiate an option and further disclosure will be provided at that time, if applicable.
3. TSX-V acceptance: The investor relations engagement of Proconsul Capital Ltd. is subject to acceptance by the TSX Venture Exchange.

The company confirms that it is in compliance with TSX-V Policy 3.4 regarding investor relations, promotional and market-making activities.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors.

We seek Safe Harbor.